Danish pharmaceutical giant Novo Nordisk officially introduced its highly popular diabetes medication Ozempic in the Indian market on Friday, marking a major
expansion in the world’s most populous nation amid surging demand for diabetes and weight-management treatments, said an ET report. The once-weekly injectable, containing the active ingredient semaglutide, will be available in three dose strengths: 0.25 mg, 0.5 mg, and 1 mg. Pricing in India:
- 0.25 mg dose: Rs 2,200 per pen ( Rs 8,800 per month)
- 0.5 mg dose: Rs 10,170 per month
- 1 mg dose: Rs 11,175 per month
Novo Nordisk secured regulatory approval to import and market Ozempic in India in September 2025.With over 77 million adults living with type 2 diabetes — the second-highest number globally after China — and obesity rates rising rapidly, India represents a critical growth market for GLP-1 receptor agonists like Ozempic.
Analysts project the worldwide market for such weight-loss and diabetes drugs could reach up to $150 billion annually by the end of the decade.
Originally approved by the U.S. FDA in 2017 for type 2 diabetes management, Ozempic has achieved blockbuster status worldwide, driven in part by widespread off-label use for weight loss due to its powerful appetite-suppressing effects. Novo Nordisk markets the identical semaglutide formulation specifically for chronic weight management under the brand name Wegovy in countries where it is approved for that indication.
The launch strengthens Novo Nordisk’s foothold in India’s fast-growing diabetes and obesity treatment segment, where it already sells other semaglutide products such as Rybelsus (oral) and the lower-dose Victoza.
